Pramipexole dihydrochloride

Pramipexole dihydrochloride Synonym: PRAMIPEXOLE DIHYDROCHLORIDE;PRAMIPEXOLE HCL;PRAMIPEXOLE HYDROCHLORIDE;PRAMIPEXOL HCL;(s)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride;PramipexoleDihcl;(S)-2-Amino-6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol2HCltetrahydrobenzothiazol;(s)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine, Dihydrochloride CAS: 104632-25-9 MF: C10H19Cl2N3S MW: 284.25 Assay: 99% Appearance: White liquid Specification: CP Property: Pramipexole has protective effect on the damaged neurons, jitter symptom control well, side effects in the Parkinson area at least, and later revised Drug larger space, conducive to the follow-up treatment, can avoid the nerve damage caused by long-term use of levodopa, delaying the need to levodopa treatment time, reducing the dose of levodopa. Usage: Two therapeutic effects of pramipexole hydrochloride in the treatment of Parkinson's disease: 1. to alleviate the symptoms of Parkinson's disease: Parkinson's disease is due to the movement of brain dopaminergic neuron loss caused by dopamine deficiency, lead to patients with tremor, rigidity and bradykinesia and a series of symptoms. Hydrochloric acid highly selective effects on dopamine D2 and D3 receptor agonist, dopamine release, improve motor symptoms. Research on Shannon display, early Parkinson's disease patients pramipexole monotherapy after, can effectively control the motor symptoms in patients with early stage, to help maintain the ability of daily life. Pramipexole in combination with levodopa can effectively improve the ADL score and motor symptoms in patients with advanced Parkinson's disease score in patients with advanced Parkinson's disease, make life more vibrant. 2. significantly improve the depressive symptoms in patients with Parkinson's disease: pramipexole hydrochloride is dopamine D2 receptor agonist, D3, and the system of dopamine D3 receptor may be associated with emotions and behavior, pramipexole can selectively stimulate D3 receptors, and the D3 receptor agonist more higher than that of D2 receptor, could significantly relieve the symptoms of depression. In the study of Italy Barone, were treated with pramipexole or sertraline in the treatment of depression in patients with Parkinson's disease, pramipexole group with depression symptoms in patients with a significantly higher percentage of sertraline group. Researchers think, dopamine receptor agonist (pramipexole) alternative antidepressant treatment for Parkinson's disease patients with depression. Package: 1kg/fluoride bottle